A Study of CM310 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

884

Participants

Timeline

Start Date

September 13, 2024

Primary Completion Date

April 29, 2032

Study Completion Date

October 31, 2032

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

CM310

CM310 Recombinant Humanized Monoclonal Antibody Injection

DRUG

Placebo

All Listed Sponsors

lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT06547333 - A Study of CM310 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease | Biotech Hunter | Biotech Hunter